DUBLIN, Ireland – Shares in Merrion Pharmaceuticals plc (DUBLIN:MERR) surged 42 percent Monday on news that the company had secured a licensing deal with Novo Nordisk for the oral delivery of the latter company's proprietary insulin analogues. (BioWorld International)